全文获取类型
收费全文 | 24556篇 |
免费 | 1533篇 |
国内免费 | 176篇 |
专业分类
耳鼻咽喉 | 235篇 |
儿科学 | 523篇 |
妇产科学 | 467篇 |
基础医学 | 3687篇 |
口腔科学 | 259篇 |
临床医学 | 2323篇 |
内科学 | 6150篇 |
皮肤病学 | 365篇 |
神经病学 | 2119篇 |
特种医学 | 1072篇 |
外国民族医学 | 8篇 |
外科学 | 4213篇 |
综合类 | 69篇 |
一般理论 | 4篇 |
预防医学 | 1347篇 |
眼科学 | 211篇 |
药学 | 1356篇 |
中国医学 | 41篇 |
肿瘤学 | 1816篇 |
出版年
2023年 | 135篇 |
2022年 | 220篇 |
2021年 | 606篇 |
2020年 | 364篇 |
2019年 | 585篇 |
2018年 | 691篇 |
2017年 | 465篇 |
2016年 | 559篇 |
2015年 | 713篇 |
2014年 | 936篇 |
2013年 | 1204篇 |
2012年 | 1917篇 |
2011年 | 1892篇 |
2010年 | 1094篇 |
2009年 | 1104篇 |
2008年 | 1685篇 |
2007年 | 1698篇 |
2006年 | 1662篇 |
2005年 | 1703篇 |
2004年 | 1572篇 |
2003年 | 1481篇 |
2002年 | 1391篇 |
2001年 | 206篇 |
2000年 | 148篇 |
1999年 | 216篇 |
1998年 | 264篇 |
1997年 | 231篇 |
1996年 | 190篇 |
1995年 | 159篇 |
1994年 | 117篇 |
1993年 | 143篇 |
1992年 | 108篇 |
1991年 | 81篇 |
1990年 | 80篇 |
1989年 | 55篇 |
1988年 | 58篇 |
1987年 | 41篇 |
1986年 | 54篇 |
1985年 | 46篇 |
1984年 | 39篇 |
1983年 | 49篇 |
1982年 | 41篇 |
1981年 | 48篇 |
1980年 | 37篇 |
1979年 | 21篇 |
1978年 | 16篇 |
1977年 | 15篇 |
1976年 | 14篇 |
1975年 | 18篇 |
1972年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
921.
922.
923.
924.
Philippe Arbeille Didier Chaput Kathryn Zuj Arielle Depriester Alain Maillet Olivier Belbis Patrice Benarroche Sebastien Barde 《Ultrasound in medicine & biology》2018,44(11):2406-2412
Echography is the most appropriate imaging modality for investigating astronauts. Unfortunately, it requires a great deal of training to perform ultrasound examinations, which can be difficult and time consuming, especially if the astronaut does not have a medical background. We designed a new echography system with motorized probes that allows for the majority of exam functions to be controlled by a ground-based sonographer. Using tele-operation, the sonographer controls the orientation of the transducer (tilt, rotation) and echograph settings (gain, depth, freeze) and triggers ultrasound functions (pulsed wave color Doppler, 3-D capture, radiofrequency data collection, elastography). With this system, astronauts are required to hold the motorized probe only at the locations indicated, with the remainder of the exam being conducted by the ground-based sonographer. During spaceflight, ultrasound imaging of the carotid artery, jugular vein, thyroid, liver, gallbladder, biliary tract and portal vein (2-D, 3-D, color, pulsed wave, radiofrequency) were successfully performed. 相似文献
925.
926.
Troglitazone is one of the thiazolidinedione (TZD) class of anti-diabetic drugs and a ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). Troglitazone and other PPARgamma ligands have been shown to inhibit cell proliferation and induce cell cycle arrest in a variety of cancer cells, and have been considered as potential tumor preventive and tumor therapeutic agents. Little is known, however, about how normal or initiated cells respond to these agents during mouse skin carcinogenesis. We report here that troglitazone and another TZD, ciglitazone, dramatically inhibited mitogen-induced cellular proliferation in normal mouse skin primary keratinocytes and in the C50 keratinocyte cell line. This was accompanied by induction of cell cycle G1 phase arrest and suppression of cyclin D1, cdk4, and cdk2 expression. Troglitazone suppressed cyclin D1 expression at multiple levels. In addition, we demonstrated that PPARgamma was not expressed at functional levels in cultured mouse skin keratinocytes, and that the inhibitory effects of troglitazone on cellular proliferation and cyclin D1 expression in these cells were PPARgamma-independent. Given the important role of keratinocyte proliferation in skin carcinogenesis, our data suggest that TZD may be useful tumor preventive agents in skin. 相似文献
927.
Can we predict postprocedural paravalvular leak after Edwards SAPIEN transcatheter aortic valve implantation? 下载免费PDF全文
Yusuke Watanabe MD Thierry Lefèvre MD Takahide Arai MD PhD Kentaro Hayashida MD PhD Erik Bouvier MD Thomas Hovasse MD Mauro Romano MD Bernard Chevalier MD Philippe Garot MD Patrick Donzeau‐Gouge MD Arnaud Farge MD Bertrand Cormier MD Marie‐Claude Morice MD 《Catheterization and cardiovascular interventions》2015,86(1):144-151
928.
Yakoub-Agha I Mary JY Hulin C Doyen C Marit G Benboubker L Voillat L Moreau P Berthou C Stoppa AM Maloisel F Rodon P Dib M Pegourie B Casassus P Slama B Damaj G Zerbib R Harousseau JL Mohty M Facon T;Intergroupe Francophone du Myélome 《European journal of haematology》2012,88(3):249-259
This multicentre prospective randomised trial compared the efficacy and safety of two doses of thalidomide in patients with relapsed or refractory myeloma. The study was designed to test the non-inferior efficacy and to confirm the better tolerability of low-dose thalidomide as compared to a higher dose. Four hundred patients were randomly assigned to receive either 100 or 400 mg/day of thalidomide. Dexamethasone treatment was added in both arms for patients with stable disease or treatment failure at 12 weeks. The primary endpoint was 1-year overall survival (OS). Thalidomide 100 mg/day was better tolerated than 400 mg/day with less high-grade somnolence, constipation, nausea/vomiting and peripheral neuropathy (P < 0.001, P = 0.007, P = 0.03 and P = 0.007, respectively). In the per-protocol population (PP), the estimated 1-year OS rates were of 74.5% (n = 149) and 67.3% (n = 156) in the 400 and 100 groups, respectively. The upper limit of the difference between these rates was of 15.6% higher than the non-inferiority acceptable limit of 12.75%, and the hypothesis of non-inferiority of 100 could not be established (P = 0.14). On the other hand, when intent-to-treat (ITT) population was analysed, the non-inferiority was demonstrated because the 1-year OS rates were of 72.8% (n = 195) and 68.8% (n = 205) in the same groups, leading to an upper limit of the difference of 11.49% lower than the non-inferiority acceptable limit. In addition, in patients alive 12 weeks postrandomisation and those who received thalidomide plus dexamethasone, there were no significant differences in response rates, time to progression, progression-free survival and OS between the two groups. Collectively, low-dose thalidomide 100 mg/day has significant activity in advanced myeloma with an improved safety profile and can be a good salvage therapy in combination with dexamethasone. 相似文献
929.
930.